Literature DB >> 28031235

HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.

Elizabeth A Mazzio1, Karam F A Soliman2.   

Abstract

BACKGROUND/AIM: Aggressive tumor malignancies are a consequence of delayed diagnosis, epigenetic/phenotype changes and chemo-radiation resistance. Histone deacetylases (HDACs) are a major epigenetic regulator of transcriptional repression, which are highly overexpressed in advanced malignancy. While original chemotherapy drugs were modeled after phytochemicals elucidated by botanical screenings, HDAC inhibitors (HDACi) such as apicidin, trichostatin A (TSA) and butyrate were discovered as products of fungus and microbes, in particular, gut microbiota. Therefore, a persistent question remains as to the inherent existence of HDACis in raw undigested dietary plant material. In this study, we conduct a high-throughput (HTP) screening of ~1,600 non-fermented commonly used nutraceuticals (spices, herbs, teas, vegetables, fruits, seeds, rinds etc.) at (<600 μg/ml) and food-based polyphenolics (<240 μg/ml) for evidence of HDAC activity inhibition in nuclear HeLa cell lysates.
MATERIALS AND METHODS: Human HDAC kinetic validation was performed using a standard fluorometric activity assay, followed by an enzymatic-linked immuno-captured ELISA. Both methods were verified using HDACi panel drugs: TSA, apicidin, suberohydroxamic acid, M344, CL-994, valproic acid and sodium phenylbutyrate. The HTP screening was then conducted, followed by a study comparing biological effects of HDACis in HeLa cells, including analysis of whole-transcriptome non-coding RNAs using Affymetrix miRNA 4.1-panel arrays.
RESULTS: The HTP screening results confirmed 44/1600 as potential HDACis to which 31 were further eliminated as false-positives. Methodological challenges/concerns are addressed regarding plant product false-positives that arise from the signal reduction of commercial lysine development reagents. Only 13 HDACis were found having an IC50 under <200 μg/ml: Grapeseed extract (Vitis vinifera), Great burnet root (Sanguisorba Officinalis), Babul (Acacia arabica), Chinese gallnut (Melaphis chinensis), Konaberry extract (Coffea arabica), Uva Ursi (Arctostaphylos uva ursi), Green tea (Camellia sinensis), Meadowsweet (Filipendula ulmaria), Sassafras (Sassafras officinale), Turkey rhubarb (Rheum palmatum), epigallocatechin gallate (EGCG), gossypol and gallic acid. Next, we investigate the biological consequence of HDACi panel drugs in HeLa cells, where the data suggest predominant effects are anti-mitotic rather than cytotoxic. Lastly, differential effects of TSA vs. GSE at sub-lethal concentrations tested on HeLa cells show 6,631 miRNAs expressed in resting cells, 35 significantly up-regulated (TSA) and 81 up-regulated (GSE), with several miRNAs overlapping in the upward direction by both GSE and TSA (e.g. hsa-miR-23b-5p, hsa-miR-27b-5p, hsa-miR-1180-3p, hsa-miR-6880-5p and hsa-mir-943). Using DIANA miRNA online tools, it was determined that GSE and TSA simultaneously cause overexpression of similar miRNAs predicted to destroy the following influential oncogenes: NFkB, NRAS, KRAS, HRAS, MYC, TGFBR1, E2F1, E2F2, BCL21, CDKN1A, CDK6, HIF1a, and VEGFA.
CONCLUSION: The data from this study show that plant- based HDACis are relatively rare, and can elicit a similar pattern to TSA in up-regulating miRNAs involved with tumor suppression of HeLa cervical carcinoma. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  HDAC; HeLa cells; Screening; TSA; grapeseed; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28031235      PMCID: PMC5267498          DOI: 10.21873/cgp.20016

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  47 in total

1.  Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.

Authors:  Chutima Kaewpiboon; Ratakorn Srisuttee; Waraporn Malilas; Jeong Moon; Sangtaek Oh; Hye Gwang Jeong; Randal N Johnston; Wanchai Assavalapsakul; Young-Hwa Chung
Journal:  Mol Med Rep       Date:  2014-11-14       Impact factor: 2.952

2.  Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines.

Authors:  Junfen Ma; Xiaobing Guo; Shijie Zhang; Hongchun Liu; Jing Lu; Ziming Dong; Kangdong Liu; Liang Ming
Journal:  Mol Med Rep       Date:  2015-01-28       Impact factor: 2.952

3.  Grape seed proanthocyanidins reactivate silenced tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators.

Authors:  Mudit Vaid; Ram Prasad; Tripti Singh; Virginia Jones; Santosh K Katiyar
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-27       Impact factor: 4.219

4.  Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Alan R Kristal; Sandi L Navarro; Johanna W Lampe; Ulrike Peters; Ruth E Patterson; Emily White
Journal:  Nutr Cancer       Date:  2011       Impact factor: 2.900

5.  Targeting epigenetics for cancer prevention by dietary cancer preventive compounds--the case of miRNA.

Authors:  Ah-Ng Tony Kong; Chengyue Zhang; Zheng-Yuan Su
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-17

Review 6.  Histone deacetylase inhibitors from microorganisms: the Astellas experience.

Authors:  Yuhta Masuoka; Nobuaki Shindoh; Noriaki Inamura
Journal:  Prog Drug Res       Date:  2008

7.  Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Authors:  Huang Zhijun; Wang Shusheng; Min Han; Li Jianping; Qin Li-Sen; Li Dechun
Journal:  Tumour Biol       Date:  2016-02-01

8.  Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.

Authors:  Xuan Zhang; Shu-Juan Jiang; Bin Shang; Hong-Juan Jiang
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

9.  Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Authors:  Sofia R Gameiro; Anthony S Malamas; Kwong Y Tsang; Soldano Ferrone; James W Hodge
Journal:  Oncotarget       Date:  2016-02-16

10.  Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.

Authors:  Mei-Chuan Chen; Hui-Hsuan Huang; Chin-Yu Lai; Yi-Jyun Lin; Jing-Ping Liou; Mei-Jung Lai; Yu-Hsuan Li; Che-Ming Teng; Chia-Ron Yang
Journal:  Oncotarget       Date:  2016-01-05
View more
  3 in total

Review 1.  Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials.

Authors:  Olga Renner; Mascha Mayer; Christian Leischner; Markus Burkard; Alexander Berger; Ulrich M Lauer; Sascha Venturelli; Stephan C Bischoff
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26

2.  Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma.

Authors:  Mascha Mayer; Alexander Berger; Christian Leischner; Olga Renner; Markus Burkard; Alexander Böcker; Seema Noor; Timo Weiland; Thomas S Weiss; Christian Busch; Ulrich M Lauer; Stephan C Bischoff; Sascha Venturelli
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-01

Review 3.  Science and Healthy Meals in the World: Nutritional Epigenomics and Nutrigenetics of the Mediterranean Diet.

Authors:  Fabio Caradonna; Ornella Consiglio; Claudio Luparello; Carla Gentile
Journal:  Nutrients       Date:  2020-06-11       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.